ADOR appoints Nadhim Zahawi to lead Advisory Board

LEI: 213800FLQUB9J289RU66

16 January 2025

BATM Advanced Communications Limited

("BATM" or "the Group") 

ADOR Diagnostics appoints Nadhim Zahawi to lead its Advisory Board

Former Chancellor of the Exchequer and Vaccine Deployment Minister of the British Government and established global businessman to provide strategic guidance and advice as ADOR progresses towards commercialisation

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, is delighted to announce that ADOR Diagnostics ("ADOR"), an associate company of the Group, has appointed the Rt. Hon Nadhim Zahawi as Chairman of its Advisory Board. Mr. Zahawi, who brings a wealth of experience in government and business, will provide strategic guidance and advice to support ADOR as it enters the next phase of its growth strategy to commercialise its extensive R&D and transform healthcare through cutting-edge diagnostic solutions.

Mr. Zahawi began his career in business before co-founding YouGov in 2000, which became one of the world's largest polling and market research companies, having listed on the London Stock Exchange in 2005, and now employs over 400 people across three continents. In 2010, he became a Member of Parliament and held several roles in the British Government, including serving as Chancellor of the Exchequer, Secretary of State for Education and as Minister for COVID-19 Vaccine Deployment.

ADOR's NATlab molecular biology platform is currently undergoing pre-clinical validation at the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome, Italy, a leading centre for infectious disease research and treatment. Successful completion of the pre-clinical validation is expected to enable initial sales of the NATlab and the commencement of the regulatory process under the European Union In Vitro Diagnostic Medical Device Regulation to become eligible for sale in the EU market.      

Moti Nagar, Chief Executive Officer of BATM, said: "We are thrilled that Nadhim Zahawi has joined the Advisory Board at ADOR. His wealth of experience and success across both private enterprise and government, including from his time working on the UK's COVID vaccine rollout, will be invaluable as ADOR progresses to the next stage in its journey to commercialise its disruptive diagnostic solutions that aim to transform how disease is detected and managed. This is a very exciting moment for ADOR and we look to the future with great confidence."

Rt. Hon Nadhim Zahawi commented: "I am delighted to join ADOR to chair its Advisory Board. The potential for health tech to change the world is only just starting to be grasped. For individuals and for families, ADOR Diagnostics provides a concrete opportunity for a healthier, better life and a release from suffering and concern. For whole nations struggling under ever-increasing healthcare budgets, they will provide amazing tools to help transform treatment. I saw the impact great healthcare innovations have through the COVID pandemic, and am excited to help ADOR take the fight to disease and ill health and change face of diagnosis."

Enquiries

Forward-looking statements  

This document contains forward-looking statements. Those statements reflect the current opinions, evaluations and estimations of the Group's management, and are based on the current data regarding the Group's business as is detailed in this document and in the Group's periodical, interim and immediate reports. The Group does not undertake any obligation or make any representation that actual results and events will be in line with those statements, and stresses that they may differ materially from those statements, due to changes in the Group's business, market, competition, demand for the Group's products or services, general economic factors or other factors that can influence the Group's business and results, due to the risk factors that are detailed in the Group's Annual Report, and due to information and factors that are currently unknown to the Group's management and that, if known, would affect the management's opinions, evaluations or estimations. The Group will report the actual results and events according to its legal, accounting and regulatory obligations, and does not undertake any other obligation to report them or their deviations from the forward-looking statements, or to update any of the forward-looking statements in this document or to report that it is not valid anymore.